Brian Newsom
CEO
Carrigent
This startup provides vector technology solutions for viral and non-viral payload delivery, offering services such as plasmid optimization, vector design, cell line development, gene editing, and preclinical viral production. They serve the cell and gene therapy markets, enabling advancements in therapeutic developments.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Current payload delivery systems for cell and gene therapies face limitations in payload size, cell-specific targeting, and potential toxicity, hindering the effective treatment of diseases ranging from monogenic disorders to cancer and neurodegenerative conditions. Existing viral vector technologies like AAV and LNPs also present challenges related to immunogenicity and manufacturing scalability.
Solution
Carrigent offers CARGO, a patent-pending, cell-specific delivery system designed to overcome the limitations of traditional methods. This technology enables the targeted delivery of protein or genetic material _in vivo_, with increased loading capacity and reduced systemic toxicity. CARGO is a versatile platform suitable for a range of payloads, facilitating dynamic treatment approaches with controlled durability of therapeutic response. By offering high specificity to cell types and low immunogenic risk through non-viral delivery, CARGO aims to improve therapeutic outcomes while minimizing potential side effects.
Target Audience
Carrigent's primary customers are biotechnology companies and research institutions focused on cell and gene therapy development, seeking advanced delivery solutions for a variety of therapeutic applications.
Features
- Patent-pending CARGO technology for cell-specific payload delivery
- Increased payload capacity compared to traditional viral vectors
- Precision targeting to specific cell types for enhanced efficacy
- Suitable for delivery of RNA, DNA, or protein payloads
- Versatile platform for both transient and long-term transgene expression
- Non-viral delivery technology to minimize immunogenic risk
- Potential for lower dose requirements due to enhanced targeting